G1 Therapeutics (GTHX) IPO Opens Flat

Today's IPO for G1 Therapeutics, Inc. (NASDAQ: GTHX) opened for trading at $15 after pricing its initial public offering of 7,000,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $105,000,000.

In addition, G1 Therapeutics has granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of its common stock at the initial public offering price.

J.P. Morgan Securities LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Needham & Company, LLC and Wedbush Securities Inc. are acting as co-managers for the offering.

G1 Therapeutics is a clinical-stage biopharmaceutical company developing novel, small-molecule therapies that address significant unmet needs in the treatment of cancer. The company is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. G1 is based in Research Triangle Park, NC.

You May Also Be Interested In

• CopperTech Metals launches IPO roadshow on NYSE at $16-$18 per share
• Gores Holdings XI prices $312M IPO on Nasdaq
• Backblaze Inc (BLZE) PT Raised to $14 at Needham